In this study, we identified compound 1105486 as the first selective small-molecule inhibitor of β-1,4-galactosyltransferase 1 (B4GALT1) through transcriptomics-guided target discovery and structure-based virtual screening, and validated its in vitro efficacy in pancreatic cancer models. This evidence concerns the gene B4GALT1 and pancreatic neoplasm.